vs
Side-by-side financial comparison of CSX Corporation (CSX) and Kenvue (KVUE). Click either name above to swap in a different company.
Kenvue is the larger business by last-quarter revenue ($3.8B vs $3.5B, roughly 1.1× CSX Corporation). CSX Corporation runs the higher net margin — 23.2% vs 8.7%, a 14.4% gap on every dollar of revenue. On growth, Kenvue posted the faster year-over-year revenue change (3.2% vs 1.7%). CSX Corporation produced more free cash flow last quarter ($793.0M vs $744.0M). Over the past eight quarters, Kenvue's revenue compounded faster (-1.5% CAGR vs -3.0%).
CSX Transportation, known colloquially as simply CSX, is a Class I freight railroad company operating in the Eastern United States and the Canadian provinces of Ontario and Quebec. Operating about 21,000 route miles (34,000 km) of track, it is the leading subsidiary of CSX Corporation, a Fortune 500 company headquartered in Jacksonville, Florida.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
CSX vs KVUE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5B | $3.8B |
| Net Profit | $807.0M | $330.0M |
| Gross Margin | — | 56.5% |
| Operating Margin | 29.9% | 14.2% |
| Net Margin | 23.2% | 8.7% |
| Revenue YoY | 1.7% | 3.2% |
| Net Profit YoY | 401.2% | 12.6% |
| EPS (diluted) | — | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $3.8B | ||
| Q3 25 | $3.6B | $3.8B | ||
| Q2 25 | $3.6B | $3.8B | ||
| Q1 25 | $3.4B | $3.7B | ||
| Q4 24 | $3.5B | $3.7B | ||
| Q3 24 | $3.6B | $3.9B | ||
| Q2 24 | $3.7B | $4.0B |
| Q1 26 | $807.0M | — | ||
| Q4 25 | $720.0M | $330.0M | ||
| Q3 25 | $694.0M | $398.0M | ||
| Q2 25 | $829.0M | $420.0M | ||
| Q1 25 | $646.0M | $322.0M | ||
| Q4 24 | $720.0M | $293.0M | ||
| Q3 24 | $894.0M | $383.0M | ||
| Q2 24 | $963.0M | $58.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.5% | ||
| Q3 25 | — | 59.1% | ||
| Q2 25 | — | 58.9% | ||
| Q1 25 | — | 58.0% | ||
| Q4 24 | — | 56.5% | ||
| Q3 24 | — | 58.5% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | 29.9% | — | ||
| Q4 25 | 31.6% | 14.2% | ||
| Q3 25 | 30.3% | 16.7% | ||
| Q2 25 | 35.9% | 18.0% | ||
| Q1 25 | 30.4% | 14.9% | ||
| Q4 24 | 30.8% | 13.2% | ||
| Q3 24 | 37.4% | 16.8% | ||
| Q2 24 | 39.1% | 3.9% |
| Q1 26 | 23.2% | — | ||
| Q4 25 | 20.5% | 8.7% | ||
| Q3 25 | 19.3% | 10.6% | ||
| Q2 25 | 23.2% | 10.9% | ||
| Q1 25 | 18.9% | 8.6% | ||
| Q4 24 | 20.3% | 8.0% | ||
| Q3 24 | 24.7% | 9.8% | ||
| Q2 24 | 26.0% | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | $0.39 | $0.16 | ||
| Q3 25 | $0.37 | $0.21 | ||
| Q2 25 | $0.44 | $0.22 | ||
| Q1 25 | $0.34 | $0.17 | ||
| Q4 24 | $0.38 | $0.16 | ||
| Q3 24 | $0.46 | $0.20 | ||
| Q2 24 | $0.49 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $1.1B |
| Total DebtLower is stronger | $18.9B | — |
| Stockholders' EquityBook value | $13.6B | $10.8B |
| Total Assets | $44.2B | $27.1B |
| Debt / EquityLower = less leverage | 1.39× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $5.0M | $1.1B | ||
| Q3 25 | $6.0M | $1.1B | ||
| Q2 25 | $6.0M | $1.1B | ||
| Q1 25 | $8.0M | $1.1B | ||
| Q4 24 | $72.0M | $1.1B | ||
| Q3 24 | $12.0M | $1.1B | ||
| Q2 24 | $4.0M | $1.0B |
| Q1 26 | $18.9B | — | ||
| Q4 25 | $18.2B | — | ||
| Q3 25 | $18.6B | — | ||
| Q2 25 | $18.6B | — | ||
| Q1 25 | $18.5B | — | ||
| Q4 24 | $17.9B | — | ||
| Q3 24 | $18.5B | — | ||
| Q2 24 | $18.0B | — |
| Q1 26 | $13.6B | — | ||
| Q4 25 | $13.2B | $10.8B | ||
| Q3 25 | $12.8B | $10.6B | ||
| Q2 25 | $12.4B | $10.7B | ||
| Q1 25 | $12.2B | $10.1B | ||
| Q4 24 | $12.5B | $9.7B | ||
| Q3 24 | $12.9B | $10.6B | ||
| Q2 24 | $12.6B | $10.2B |
| Q1 26 | $44.2B | — | ||
| Q4 25 | $43.7B | $27.1B | ||
| Q3 25 | $43.3B | $27.2B | ||
| Q2 25 | $42.9B | $27.1B | ||
| Q1 25 | $43.2B | $26.3B | ||
| Q4 24 | $42.8B | $25.6B | ||
| Q3 24 | $43.1B | $26.9B | ||
| Q2 24 | $42.4B | $26.4B |
| Q1 26 | 1.39× | — | ||
| Q4 25 | 1.38× | — | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | 1.50× | — | ||
| Q1 25 | 1.52× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.43× | — | ||
| Q2 24 | 1.42× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3B | $854.0M |
| Free Cash FlowOCF − Capex | $793.0M | $744.0M |
| FCF MarginFCF / Revenue | 22.8% | 19.7% |
| Capex IntensityCapex / Revenue | — | 2.9% |
| Cash ConversionOCF / Net Profit | 1.58× | 2.59× |
| TTM Free Cash FlowTrailing 4 quarters | $2.0B | $1.7B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $854.0M | ||
| Q3 25 | $1.3B | $294.0M | ||
| Q2 25 | $635.0M | $621.0M | ||
| Q1 25 | $1.3B | $428.0M | ||
| Q4 24 | $1.4B | $793.0M | ||
| Q3 24 | $1.7B | $249.0M | ||
| Q2 24 | $1.1B | $440.0M |
| Q1 26 | $793.0M | — | ||
| Q4 25 | $709.0M | $744.0M | ||
| Q3 25 | $607.0M | $196.0M | ||
| Q2 25 | $-141.0M | $533.0M | ||
| Q1 25 | $536.0M | $249.0M | ||
| Q4 24 | $550.0M | $661.0M | ||
| Q3 24 | $1.1B | $190.0M | ||
| Q2 24 | $547.0M | $350.0M |
| Q1 26 | 22.8% | — | ||
| Q4 25 | 20.2% | 19.7% | ||
| Q3 25 | 16.9% | 5.2% | ||
| Q2 25 | -3.9% | 13.9% | ||
| Q1 25 | 15.7% | 6.7% | ||
| Q4 24 | 15.5% | 18.1% | ||
| Q3 24 | 29.3% | 4.9% | ||
| Q2 24 | 14.8% | 8.8% |
| Q1 26 | — | — | ||
| Q4 25 | 19.3% | 2.9% | ||
| Q3 25 | 20.4% | 2.6% | ||
| Q2 25 | 21.7% | 2.3% | ||
| Q1 25 | 21.0% | 4.8% | ||
| Q4 24 | 23.7% | 3.6% | ||
| Q3 24 | 17.3% | 1.5% | ||
| Q2 24 | 14.6% | 2.3% |
| Q1 26 | 1.58× | — | ||
| Q4 25 | 1.93× | 2.59× | ||
| Q3 25 | 1.93× | 0.74× | ||
| Q2 25 | 0.77× | 1.48× | ||
| Q1 25 | 1.94× | 1.33× | ||
| Q4 24 | 1.93× | 2.71× | ||
| Q3 24 | 1.89× | 0.65× | ||
| Q2 24 | 1.13× | 7.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSX
Segment breakdown not available.
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
